Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Cited by (374)

Items 101–200 of 374

1. Natural scaffolds in anticancer therapy and precision medicine
   Aloran Mazumder, Claudia Cerella, Marc F. Diederich · 2018 · Biotechnology Advances
2. The development of light-responsive, organic dye based, supramolecular nanosystems for enhanced anticancer therapy
   Hong‐Bo Cheng, Yixin Cui, Rui Wang, Nahyun Kwon, Juyoung Yoon · 2019 · Coordination Chemistry Reviews
3. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies
   Elisa ten Hacken, Rebecca Valentin, Fara Faye Regis, Jing Sun, Shanye Yin, Lillian L. Werner, Jing Deng, Michaela Gruber, Jessica Wong, Mei Zheng et al. · 2018 · JCI Insight
4. SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells
   Qiao‐Yang Sun, Ling‐Wen Ding, Kara J. Johnson, Siqin Zhou, Jeffrey W Tyner, Henry He Yang, Ngan Doan, JONATHAN W. SAID, Jin‐Fen Xiao, Xin-Yi Loh et al. · 2019 · Oncogene
5. Big-data-based edge biomarkers: study on dynamical drug sensitivity and resistance in individuals
   Tao Zeng, Wanwei Zhang, Xiangtian Yu, Xiaoping Liu, Meiyi Li, Luonan Chen · 2015 · Briefings in Bioinformatics
6. BCL-2 system analysis identifies high-risk colorectal cancer patients
   Lindner, Andreas U, Salvucci, Manuela, Morgan, Clare, Monsefi, Naser, Resler, Alexa J, Cremona, Mattia, Curry, Sarah, Toomey, Sinead, O'Byrne, Robert, Bacon, Orna et al. · 2017 · Gut
7. Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation
   Arif E. Çetin, Mark M. Stevens, Nicholas L. Calistri, Mariateresa Fulciniti, Selim Olçum, Robert J. Kimmerling, Nikhil C. Munshi, Scott R. Manalis · 2017 · Nature Communications
8. Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy
   Anna A. Popova, Pavel A. Levkin · 2020 · Advanced Therapeutics
9. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
   Stover, Elizabeth H., Baco, Maria B., Cohen, Ofir, Li, Yvonne Y., Christie, Elizabeth L., Bagul, Mukta, Goodale, Amy, Lee, Yenarae, Pantel, Sasha, Rees, Matthew G. et al. · 2019 · Molecular Cancer Research
10. BH3 mimetics as anti-fibrotic therapy: Unleashing the mitochondrial pathway of apoptosis in myofibroblasts
    Tobias Kühl, David Lagares · 2018 · Matrix Biology
11. Tissue-Agnostic Drug Development
    Keith T. Flaherty, Dung Thi Le, Steven J. Lemery · 2017 · American Society of Clinical Oncology Educational Book
12. Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1
    Justin M. Jenson, Jeremy A. Ryan, Robert A. Grant, Anthony G. Letai, Amy E. Keating · 2017 · eLife
13. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma
    Shannon M. Matulis, Vikas Anand Gupta, Paola E. Neri, Nizar Jacques Bahlis, Paulo Maciag, Joel D. Leverson, Leonard T. Heffner, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman et al. · 2019 · Leukemia
14. Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis
    Fabian Schuler, Johannes G. Weiss, Silke E. Lindner, Michael Lohmüller, Sebastian Herzog, Simon F. Spiegl, Philipp Menke, Stephan Geley, Verena Labi, Andreas Villunger · 2017 · Nature Communications
15. The pro-apoptotic Bcl-2 family member Harakiri (HRK) induces cell death in glioblastoma multiforme
    Ezgi Kaya-Aksoy, Ahmet Cingöz, Filiz Senbabaoglu, Fidan Seker-Polat, İlknur Sur‐Erdem, Alişan Kayabölen, Tolga Lokumcu, Gizem Nur Şahin, Serçin Karahüseyinoğlu, Tugba Bagci Onder · 2019 · Cell Death Discovery
16. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies
    Fevzi Yalniz, William G. Wierda · 2019 · Drugs
17. Mitochondrial apoptosis and BH3 mimetics
    Haiming Dai, X. Wei Meng, Scott H. Kaufmann · 2016 · F1000Research
18. BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
    Michael Butterworth, Andrew R. Pettitt, Shankar Varadarajan, Gerald M. Cohen · 2016 · British Journal of Cancer
19. Modulation of Bax and mTOR for Cancer Therapeutics
    Rui Li, Chunyong Ding, Jun Zhang, Maohua Xie, Dongkyoo Park, Ye Ding, Guo Chen, Guojing Zhang, Melissa Gilbert‐Ross, Wei Zhou et al. · 2017 · Cancer Research
20. Innovative Technologies Changing Cancer Treatment
    Sara Charmsaz, Maria Prencipe, Maeve Bailey‐Whyte, Graham P. Pidgeon, Denis Martin Collins · 2018 · Cancers
21. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma
    Rachel Tanos, Dipan Karmali, Srilatha Nalluri, Kelly C. Goldsmith · 2016 · BMC Cancer
22. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia
    Charles Herbaux, Christoph Kornauth, Stéphanie Poulain, Stephen Jun Fei Chong, Mary C. Collins, Rebecca Valentin, Liam R. Hackett, Olivier Tournilhac, François Lemonnier, Jehan Dupuis et al. · 2021 · Blood
23. Functional Drug Screening in the Era of Precision Medicine
    Giulia C. Napoli, William Douglas Figg, Cindy H. Chau · 2022 · Frontiers in Medicine
24. Tumor‐stroma interactions differentially alter drug sensitivity based on the origin of stromal cells
    Benjamin D. Landry, Thomas Leete, Ryan Richards, Peter Cruz‐Gordillo, Hannah R. Schwartz, Megan E. Honeywell, Gary Ren, Alyssa D. Schwartz, Shelly R. Peyton, Michael J. Lee · 2018 · Molecular Systems Biology
25. Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism
    Germana Castelli, Elvira Pelosi, Ugo Testa · 2019 · Cancers
26. Disrupting the leukemia niche in the central nervous system attenuates leukemia chemoresistance
    Leslie M. Jonart, Maryam Ebadi, Patrick Basile, Kimberly Johnson, Jessica Makori, Peter M. Gordon · 2019 · Haematologica
27. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
    Janic Le Pen, M. Laurent, Kristopher A. Sarosiek, Céline Vuillier, Fabien Gautier, Sylvie Montessuit, Jean‐Claude Martinou, Anthony G. Letai, Frédérique Braun, Philippe Paul Juin · 2016 · Cell Death and Disease
28. Neutrophil extracellular traps promote invasion and metastasis via NLRP3-mediated oral squamous cell carcinoma pyroptosis inhibition
    Rundong Zhai, Zizhen Gong, Mengqi Wang, Zihui Ni, Jiayi Zhang, Mengyao Wang, Yu Zhang, Fanrui Zeng, Ziyue Gu, Xingyu Chen et al. · 2024 · Cell Death Discovery
29. Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration
    Francisco J. Sánchez Rivera, Jeremy A. Ryan, Yadira M. Soto‐Feliciano, Mary Clare Beytagh, Lucius L. Xuan, David M. Feldser, Michael T. Hemann, Jesse R. Zamudio, Nadya Dimitrova, Anthony G. Letai et al. · 2021 · Proceedings of the National Academy of Sciences
30. Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
    Danielle S. Potter, Ruochen Du, Patrick D. Bhola, Raphael Bueno, Anthony G. Letai · 2021 · Cell Death and Disease
31. Sublethal engagement of apoptotic pathways in residual cancer
    Shane T. Killarney, Stephen W. G. Tait, Douglas R. Green, Kris C. Wood · 2023 · Trends in Cell Biology
32. The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
    Daniel A.R. Heisey, Timothy L. Lochmann, Konstantinos V. Floros, Colin M. Coon, Krista M. Powell, Sheeba Jacob, Marissa L. Calbert, Maninderjit S. Ghotra, Giovanna T. Stein, Yuki Kato Maves et al. · 2018 · Clinical Cancer Research
33. Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review)
    Jing Yuan, Hua Lan, Xiao‐Yan Jiang, Da Xing Zeng, Songshu Xiao · 2020 · International Journal of Molecular Medicine
34. Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
    Jorge Gómez Tejeda Zañudo, Pingping Mao, Clara Alcon, Kailey J. Kowalski, Gabriela N. Johnson, Guotai Xu, Jose M Baselga, Maurizio Scaltriti, Anthony G. Letai, Joan Montero et al. · 2021 · Cancer Research
35. Fatty acid synthase ( FASN ) signalome: A molecular guide for precision oncology
    Javier Abel Menéndez, Elisabet Cuyàs, José Antonio Encinar, Travis Vander Steen, Sara Verdura, Àngela Llop‐Hernández, Júlia López, Eila Serrano‐Hervás, Sílvia Osuna, Begoña Martı́n-Castillo et al. · 2023 · Molecular Oncology
36. Dynamic BH3 profiling-poking cancer cells with a stick
    Joan Montero, Anthony G. Letai · 2016 · Molecular & Cellular Oncology
37. Remodeling of mitochondrial morphology and function: an emerging hallmark of cellular reprogramming
    Anuj Rastogi, Piyush K. Joshi, Ela Contreras, Vivian Gama · 2019 · Cell Stress
38. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
    Jason J. Zoeller, Aleksandr Vagodny, Veerle W. Daniëls, Krishan L. Taneja, Benjamin Yongcheng Tan, Yoko S. DeRose, Maihi Fujita, Alana L. Welm, Anthony G. Letai, Joel D. Leverson et al. · 2020 · Breast Cancer Research
39. Application of precision medicine in clinical routine in haematology—Challenges and opportunities
    Tove Wästerlid, Lucia B. Cavelier, Claudia Haferlach, Marina Y Konopleva, Stefan Fröhling, Päivi Östling, Lars Bullinger, Thoas Fioretos, Karin Ekstrom Ekstroem Smedby · 2022 · Journal of Internal Medicine
40. Biphasic ROS production, p53 and BIK dictate the mode of cell death in response to DNA damage in colon cancer cells
    Özgür Kütük, Nurgül Aytan, Bahriye Karakaş, Aslı Giray Kurt, Ufuk Acikbas, Şehime Gülsün Temel, Hüveyda Başağa · 2017 · PLoS ONE
41. BCL-2 Inhibitors, Present and Future
    Christine E. Ryan, Matthew Steven Davids · 2019 · The Cancer Journal
42. MCL-1 is a clinically targetable vulnerability in breast cancer
    Matthew L. Winder, Kirsteen J. Campbell · 2022 · Cell Cycle
43. S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver
    Anthony G. Letai · 2016 · Cancer Cell
44. Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
    Andrew R. Conery, Richard C. Centore, Kerry L. Spillane, Nicole E. Follmer, Archana Bommi‐Reddy, Charlie Hatton, Barbara M. Bryant, Patricia Greninger, Arnaud Amzallag, Cyril H. Benes et al. · 2016 · Cancer Research
45. Discovery of Small Molecule Bak Activator for Lung Cancer Therapy
    Dongkyoo Park, Abu Syed Md Anisuzzaman, Andrew T. Magis, Guo Chen, Maohua Xie, Guojing Zhang, Madhusmita Behera, Gabriel Sica, Suresh S. Ramalingam, Taofeek Kunle Owonikoko et al. · 2021 · Theranostics
46. Tuning ultrasmall theranostic nanoparticles for MRI contrast and radiation dose amplification
    Needa A. Virani, Paul Rocchi, Léna Carmès, Romy Guthier, Iyer Meghna, Léa Seban, Toby Morris, Stephanie Bennett, Michael T. Lavelle, Johany Peñailillo et al. · 2023 · Theranostics
47. Monitoring drug induced apoptosis and treatment sensitivity in non-small cell lung carcinoma using dielectrophoresis
    Rajeshwari Taruvai Kalyana Kumar, Shanshan Liu, John Dorrance Minna, Shalini Prasad · 2016 · Biochimica et Biophysica Acta (BBA) - General Subjects
48. High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells
    Thomas L. Horn, Stéphane Ferretti, Nicolas Ebel, Angela Tam, Samuel B. Ho, Fred Harbinski, Ali Farsidjani, Matthew J. Zubrowski, William R. Sellers, Robert Schlegel et al. · 2016 · Cancer Research
49. Logic Modeling in Quantitative Systems Pharmacology
    Pauline Traynard, Luis Tobalina, Federica Eduati, Laurence Calzone, Julio Sáez-Rodríguez · 2017 · CPT Pharmacometrics & Systems Pharmacology
50. NIR-triggered release of DOX from sophorolipid-coated mesoporous carbon nanoparticles with the phase-change material 1-tetradecanol to treat MCF-7/ADR cells
    Abid Hussain, Shengrong Guo · 2018 · Journal of Materials Chemistry B
51. Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells
    Nicola Michelle Bougen-Zhukov, Yasmin Nouri, Tanis D. Godwin, Megan F. Taylor, Christopher Hakkaart, Andrew Single, Tom P. Brew, Elizabeth Permina, Augustine Chen, Michael A. Black et al. · 2019 · Cancers
52. Metabolic rewiring in melanoma drug-resistant cells
    Ivi Juliana Bristot, Camila Kehl Dias, Henrique Chapola, Richard B. Parsons, Fábio Klamt · 2020 · Critical Reviews in Oncology/Hematology
53. Reduced ER–mitochondria connectivity promotes neuroblastoma multidrug resistance
    Jorida Çoku, David M. Booth, Jan Skoda, Madison C. Pedrotty, Jennifer Vogel, Kangning Liu, Annette T. Vu, Erica L. Carpenter, Jamie C. Ye, Michelle A. Chen et al. · 2022 · The EMBO Journal
54. Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses
    Oleg N. Timofeev, Boris Klimovich, Jean Schneikert, Michael Wanzel, Evangelos Pavlakis, Julia Noll, Samet Mutlu, Sabrina Elmshäuser, Andrea Nist, Marco Mernberger et al. · 2019 · The EMBO Journal
55. HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells
    Clara Alcon, Marta Kovatcheva, Paula Morales-Sánchez, Vanessa López-Polo, Teresa Torres, Susana Puig, Albert Lu, Josep Samitier, Carlos Enrich, Manuel Serrano et al. · 2024 · Cell Death and Differentiation
56. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells
    Martin A. Grundy, Sahana Balakrishnan, Matthew Fox, Claire Seedhouse, Nigel H. Russell · 2018 · Oncotarget
57. Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics
    Veerle W. Daniëls, Jason J. Zoeller, Nick van Gastel, Kelley E. McQueeney, Salma Parvin, Danielle S. Potter, Geoffrey G. Fell, Vinícius Guimarães Ferreira, Binyam Yilma, Rajat Gupta et al. · 2021 · Science Signaling
58. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
    Clara Alcon, Jorge Gómez Tejeda Zañudo, Réka Albert, Nikhil Wagle, Maurizio Scaltriti, Anthony G. Letai, Josep Samitier, Joan Montero · 2021 · Cells
59. Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance
    Sylvain Garciaz, Colombe Saillard, Yosr Hicheri, Norbert Vey · 2021 · Cancers
60. Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell!
    Anthony G. Letai · 2015 · Clinical Cancer Research
61. Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy
    Konstantinos V. Floros, Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernadó Morales, Maninderjit S. Ghotra, Carlotta Costa, Andrew James Souers et al. · 2018 · Proceedings of the National Academy of Sciences
62. Predicting Tumor Sensitivity to Chemotherapeutic Drugs in Oral Squamous Cell Carcinoma Patients
    Beaulah Mary Robert, D. Muralidharan, G.R. Brindha, Muthu Dhandapani, Thangaiyan Radhiga, Ganesan Muthusamy, Ramadas Madhavan Nirmal, Nagarajan Rajendra Prasad · 2018 · Scientific Reports
63. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma
    Oliver Weigert, David M. Weinstock · 2017 · Blood
64. Emerging approaches to target mitochondrial apoptosis in cancer cells
    Andrew P. Gilmore, Louise King · 2019 · F1000Research
65. BH3 Mimetics in Hematologic Malignancies
    Pavel Klener, Dana Sovilj, Nicol Renešová, Ladislav Anděra · 2021 · International Journal of Molecular Sciences
66. Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
    Elisabeth A. Lasater, Dhara N. Amin, Rajat Bannerji, Raghuveer Singh Mali, Kathy Barrett, Ryan N. Rys, Jason Oeh, Eva Lin, Tim Sterne‐Weiler, Ellen Ingalla et al. · 2023 · American Journal of Hematology
67. Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax
    Tamara Vervloessem, Haidar Akl, Thomas Tousseyn, Humbert DE SMEDT, Jan B. Parys, Geert Bultynck · 2017 · Oncotarget
68. A connection in life and death: The BCL-2 family coordinates mitochondrial network dynamics and stem cell fate
    Megan L. Rasmussen, Vivian Gama · 2020 · International review of cytology
69. Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
    Simonetta Maria Leto, Martina Ferri, Francesco Paolo Sassi, Eugenia Rosalinda Zanella, Francesca Cottino, Valentina Vurchio, Irene Catalano, Alessandro Ferrero, Caterina C. Zingaretti, Caterina Marchiò et al. · 2023 · Clinical Cancer Research
70. Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
    Clara Alcon, Albert Manzano-Muñoz, Estela Prada, Jaume Mora, Aroa Soriano, Gabriela Guillén, Soledad Gallego, Josep M Roma, Josep Samitier, Alberto Villanueva et al. · 2020 · Cell Death and Disease
71. Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets
    Lukas Mathur, Bence Szalai, N. H. Du, Ramesh Utharala, Martine Ballinger, Jonathan J. M. Landry, Michaël Ryckelynck, Vladimı́r Beneš, Julio Sáez-Rodríguez, Christoph A. Merten · 2022 · Nature Communications
72. Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
    Monica Pallis, Francis J. Burrows, Jeremy A. Ryan, Martin A. Grundy, Claire Seedhouse, Amina M Abdul-Aziz, Joan Montero, Anthony G. Letai, Nigel H. Russell · 2016 · Oncotarget
73. Apoptotic priming is defined by the dynamic exchange of Bcl-2 proteins between mitochondria and cytosol
    King, Louise E., Rodriguez-Enriquez, Ricardo, Pedley, Robert, Mellor, Charlotte E. L., Wang, Pengbo, Zindy, Egor, White, Michael R. H., Brennan, Keith, Gilmore, Andrew P. · 2022 · Cell Death & Differentiation
74. Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy–induced toxicities
    Johan K. E. Spetz, Mary H.C. Florido, Cameron S. Fraser, Xingping Qin, Jonathan Choiniere, Stacey J. Yu, Rumani Singh, Max Friesen, Lee L. Rubin, Joe‐Elie Salem et al. · 2022 · Science Advances
75. A Critical Appraisal of the Utility of Targeting Therapy-Induced Senescence for Cancer Treatment
    Tareq Saleh, Edward F. Greenberg, Anthony C. Faber, Hisashi Harada, David A. Gewirtz · 2025 · Cancer Research
76. Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways
    Yoriko Saito, Yoshiki Mochizuki, Ikuko Ogahara, Takashi Watanabe, Leah J. Hogdal, Shinsuke Takagi, Kaori Sato, Akiko Kaneko, Hiroshi Kajita, Naoyuki Uchida et al. · 2017 · Science Translational Medicine
77. From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs
    Valentin L’Hôte, Carl Mann, Jean‐Yves Thuret · 2022 · Open Biology
78. Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines
    Radosław Polański, J. Vincent, Urszula M. Polanska, Tudor Petreuş, ERIC K. Y. TANG · 2015 · Cell Death and Disease
79. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia
    Claire Lucas, Mateus Milani, M Butterworth, Natasha Carmell, L J Scott, Richard E. Clark, Gerald M. Cohen, Shankar Varadarajan · 2016 · Leukemia
80. Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia
    Claudia Cerella, Anthoula Gaigneaux, Aloran Mazumder, J-Y. Lee, Estelle Saland, Flavia Radogna, Thomas Farge, François Vergez, Christian Récher, Jean‐Emmanuel Sarry et al. · 2016 · Leukemia
81. Measurement of BH3-only protein tolerance
    Haiming Dai, Husheng Ding, Kevin L. Peterson, X. Wei Meng, Paula A. Schneider, Katherine L. B. Knorr, Scott H. Kaufmann · 2017 · Cell Death and Differentiation
82. How to find the right drug for each patient? Advances and challenges in pharmacogenomics
    Angeliki Kalamara, Luis Tobalina, Julio Sáez-Rodríguez · 2018 · Current Opinion in Systems Biology
83. Personalized Drug Efficacy Monitoring Chip
    Vanessa Velasco, Kushal Joshi, Jiamin Chen, Rahim Esfandyarpour · 2019 · Analytical Chemistry
84. The Role of Insulin Resistance in Cancer
    Bal Krishna Subedi, Charishma Bhimineni, Shivani Modi, Atousa Jahanshahi, Katherine Quiza, Daniel Bitetto · 2025 · Current Oncology
85. Progress in the study of molecular mechanisms of cell pyroptosis in tumor therapy
    Dong Wang, Xin Wan · 2023 · International Immunopharmacology
86. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
    Adamia, Sophia, Bhatt, Shruti, Wen, Kenneth, Chyra, Zuzana, Fell, Geoffrey G., Tai, Yu-Tzu, Pioso, Marisa S., Abiatari, Ivane, Letai, Anthony, Dorfman, David M. et al. · 2022 · Leukemia
87. WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage
    Mathilde R. W. de Jong, Myra Langendonk, Bart Reitsma, Pien Herbers, Marcel Nijland, Gerwin A. Huls, Anke van den Berg, Emanuele Ammatuna, Lydia Visser, Tom van Meerten · 2019 · Cancers
88. Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL
    Felix Seyfried, Felix Uli Stirnweiß, Alexandra Niedermayer, Stefanie Enzenmüller, Rebecca Louise Hörl, Vera Münch, Stefan Köhrer, Klaus‐Michael Debatin, Lüder Hinrich Meyer · 2022 · Leukemia
89. Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma
    Danielle S. Potter, Ruochen Du, Stephan Bohl, Kin-Hoe Chow, Keith Lloyd Ligon, Raphael Bueno, Anthony G. Letai · 2023 · Nature Communications
90. Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state
    Fleur Jochems, Chrysiida Baltira, Julie A. MacDonald, Veerle W. Daniëls, Abhijeet Mathur, Mark C. de Gooijer, Olaf van Tellingen, Anthony G. Letai, René Bernards · 2024 · Cell Death and Differentiation
91. Interleukin 21 – its potential role in the therapy of B-cell lymphomas
    Shruti Bhatt, Kristopher A. Sarosiek, Izidore S. Lossos · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
92. Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
    Ana Beatriz Varanda, Ana Martins-Logrado, Miguel Godinho Ferreira, Rita Fior · 2020 · Cancers
93. BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer
    Tomohiro Kubo, Yutaka Kawano, Nobuaki Himuro, Shintaro Sugita, Yasushi Sato, Kazuma Ishikawa, Kohichi Takada, Kazuyuki Murase, Koji Miyanishi, Tsutomu Sato et al. · 2015 · Gastric Cancer
94. Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies
    Jérôme Donnadieu, Emma Lachaier, M. Peria, Zuzana Saidak, Stéphanie Dakpé, J.-F. Ikoli, Bruno Chauffert, Cyril Page, Antoine Galmiche · 2016 · BMC Cancer
95. Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
    Maxime Jullien, Patricia Gomez‐Bougie, David Chiron, Cyrille Touzeau · 2020 · Cells
96. Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?
    Maryam Sarraf Yazdy, Anthony R. Mato, Bruce D. Cheson · 2018 · Blood
97. Endogenous and imposed determinants of apoptotic vulnerabilities in cancer
    Kristopher A. Sarosiek, Kris C. Wood · 2022 · Trends in cancer
98. Toward Systems Biomarkers of Response to Immune Checkpoint Blockers
    Óscar Lapuente-Santana, Federica Eduati · 2020 · Frontiers in Oncology
99. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells
    Mariusz L. Hartman, Anna Gajos-Michniewicz, Julita A. Talaj, Aleksandra Mielczarek-Lewandowska, Małgorzata Czyż · 2020 · Cancer Letters
100. Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependencies
     Julie A. MacDonald, Gary Andrew Bradshaw, Fleur Jochems, René Bernards, Anthony G. Letai · 2025 · Cell Death and Differentiation